Skip to Content
Merck
  • Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.

Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2012-11-01)
Theodoros Kalampokas, George Creatsas, Emmanouil Kalampokas
ABSTRACT

One of the most serious complications of assisted reproduction techniques is ovarian hyperstimulation syndrome (OHSS). OHSS not only increases morbidity and mortality in IFV cycles, but also causes significant other problems, as cancelled in vitro fertilization (IVF) cycles, prolonged hospitalization, causing emotional and sociofinancial consequences. Several treatments for OHSS have been proposed and among these Cabergoline (Cb2). Despite the above-mentioned beneficial effect, Cb2 has not been widely used in everyday's clinical practice. With our study, we try to review all studies with strong evidence examining Cb2 use for OHSS prevention.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cabergoline, ≥98% (HPLC)
Cabergoline, European Pharmacopoeia (EP) Reference Standard